First patient treatment in Italy
Sydney, Australia – 22 May 2023: The Board of OncoSil Medical Ltd (ASX: OSL) (OncoSil or the Company), a medical device company focused on treatments for patients with locally advanced pancreatic cancer (LAPC), is pleased to announce the first patient treatment in Italy with the OncoSilTM device.
The first patient treatment was undertaken at the San Camillo-Forlanini Hospital in Rome, Italy. We expect that the addition of this treatment site will enhance the recognition of the OncoSilTM device as a treatment option across Italy as well as continuing to raise the profile across Europe.
Director General of the San Camillo-Forlanini Hospital, Narciso Mostarda commented:
“Research, innovation and the courage of professionals can make a quantum leap in care, even and especially when it comes to complex or very complex diseases, such as oncology, in this case one of the most aggressive cancers we know of. There is a real need for building new ways to attack the tumour itself. The contribution of each of the professionals involved has been fundamental in reaching this goal.”.
OncoSil’s CEO and Managing Director, Mr Nigel Lange said:
“It is a significant achievement to treat our first patient in Italy and we look forward to providing hope to patients in this country with a poor prognosis from cancer of the pancreas. Every year in Italy, more than 12,000 patients do not survive their cancer diagnosis and we are pleased to commence treatments to improve the recognition of the OncoSilTM device as an option for patients with pancreatic cancer.”